Primary Objectives:
Secondary Objectives:
Additional Criteria for Inclusion in Phase 1b (PC14586 (INN: rezatapopt) + pembrolizumab combination)
Additional Criteria for Exclusion from Phase 2 (PC14586 monotherapy)
Additional Criteria for Exclusion from Phase 1b (PC14586 (INN: rezatapopt) + pembrolizumab combination)